Cardio Diagnostics Holdings (CDIO) Stock News
$CDIO · NASDAQ · HEALTHCARE · 1 stories in 30 daysBORSA has published 1 story on Cardio Diagnostics Holdings (CDIO) in the past 30 days. BORSA’s news read on CDIO is leaning bullish at 57/100, based on 1 company event over the past 7 days. Cardio Diagnostics Holdings last reported quarterly results on Nov 6, 2026, for the quarter ended Sep 30, 2026.
The wire on $CDIO
newest first · updated · direct subject stories onlyCardio Diagnostics released a whitepaper on non-obstructive coronary artery disease (NOCAD), which affects 3-4 million Americans with INOCA. The paper argues that invasive coronary angiography can miss NOCAD because it shows anatomy, not function. It positions the company's AI- and epigenetics-based PrecisionCHD blood test as a low-cost method to identify these patients earlier in primary care. The whitepaper is available for download.
bullish 60 · impact 20The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
Cardio Diagnostics Holdings (CDIO) stock: common questions
What is the latest Cardio Diagnostics Holdings stock news?
The highest-impact CDIO story BORSA published in the past 30 days: